This re-evaluation of the TP53 status in HL using a sensitive technique reinforces the concept that TP53 mutation may be involved in the pathology of some cases of HL [29] and perhaps in the genomic instability observed in this disease, as well as the occurrence of late complications, such as secondary cancer following HL treatment [30] or HL as a secondary event [6]. This evidence concerns the gene TP53 and cancer.